Is AZN or HON cheaper?

On trailing earnings, AZN is cheaper: AZN trades at a 26.92 P/E and HON at 31.21.

Which has grown faster, AZN or HON?

Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus HON at 2.42%.

Does AZN or HON pay a bigger dividend?

AZN yields 1.79% and HON yields 2.13% based on trailing dividends and the latest price.

Is AZN or HON more profitable?

AZN runs the higher net margin — AZN at 17.19% versus HON at 11.16%.

Which has been the better investment, AZN or HON?

Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus HON at 9.42%. Past performance doesn't predict future results.

AstraZeneca PLC (AZN) vs Honeywell International Inc. (HON)

AZN leads on 14 of 16 compared metrics.

A side-by-side comparison of AstraZeneca PLC and Honeywell International Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Honeywell International Inc.

$139.60B

$220.31Industrials

Total return — AZN vs HON

growth of $100 · last 30y

AZN +732.9%HON +722.7%AZN compounded faster

AZN HON

AZN vs HON: by the numbers

•AZN is the larger company ($277.22B vs $139.60B market cap).
•AZN trades at the lower earnings multiple (26.92 vs 31.21 P/E).
•AZN converts more revenue to profit (17.19% vs 11.16% net margin).
•AZN grew revenue faster over the past five years (16.99% vs 2.42% CAGR).
•HON pays the higher dividend yield (2.13% vs 1.79%).

Which is better, AZN or HON?

Metric tally: AZN 14 · HON 2

It depends on what you're optimizing for:

ValueAZN(lower P/E)

GrowthAZN(faster 5Y revenue CAGR)

IncomeHON(higher dividend yield)

QualityAZN(higher ROIC)

Metrics side by side

Valuation

Metric	AZN	HON
P/E ratio	26.92●	31.21
Forward P/E	15.33●	19.22
P/S ratio	4.62	3.83●
P/B ratio	5.90●	6.60
PEG ratio	0.14●	17.93
EV / EBITDA	14.92●	23.95
FCF yield	2.89%	2.92%

Profitability

Metric	AZN	HON
Gross margin	81.68%●	36.95%
Operating margin	23.69%●	14.87%
Net margin	17.19%●	11.16%
ROE	21.95%●	19.24%
ROIC	13.03%●	9.22%

Dividends

Metric	AZN	HON
Dividend yield	1.79%	2.13%●
Payout ratio	48.48%	63.51%

Growth (annualized)

Metric	AZN	HON
Revenue CAGR (5Y)	16.99%●	2.42%
EPS CAGR (5Y)	22.02%●	1.74%
FCF CAGR (5Y)	15.68%●	-4.80%
Total return CAGR (5Y)	11.03%●	1.55%

Frequently asked

Which is better, AZN or HON?: It depends on your goal. value: AZN (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: HON (higher dividend yield); quality: AZN (higher ROIC). Across all compared metrics, AZN leads 14 to 2.
Is AZN or HON cheaper?: On trailing earnings, AZN is cheaper: AZN trades at a 26.92 P/E and HON at 31.21.
Which has grown faster, AZN or HON?: Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus HON at 2.42%.
Does AZN or HON pay a bigger dividend?: AZN yields 1.79% and HON yields 2.13% based on trailing dividends and the latest price.
Is AZN or HON more profitable?: AZN runs the higher net margin — AZN at 17.19% versus HON at 11.16%.
Which has been the better investment, AZN or HON?: Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus HON at 9.42%. Past performance doesn't predict future results.

Go deeper

Full AZN analysis Full HON analysis Interactive comparison tool

Dig into the metrics

AstraZeneca P/E ratio Honeywell International P/E ratio AstraZeneca dividend yield Honeywell International dividend yield AstraZeneca ROE Honeywell International ROE AstraZeneca operating margin Honeywell International operating margin AstraZeneca revenue growth Honeywell International revenue growth AstraZeneca free cash flow Honeywell International free cash flow

AstraZeneca & Honeywell International appear in these rankings

Highest Dividend Yield Stocks Fastest Revenue Growth Stocks Best 10-Year Total Return Stocks Largest Companies by Market Cap

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 15, 2026.